Clinical Trials Logo

Clinical Trial Summary

It is thought that prophylactic enteral probiotics in newborns may play a role in the prevention of infection and NEC-related morbidity by preventing bacterial migration in the mucosa, reducing their number by competing with pathogenic bacteria, providing microbial balance, and increasing intestinal immunity. In our study, it was determined to detect normal D-lactic acid levels in urine in late premature (babies born after 34 weeks of gestation) and term babies, to show the negative effect of antibiotic treatment on the intestinal flora indirectly by measuring urinary D-lactic acid, and the probiotic support in babies using antibiotics was disrupted. The investigators aim to investigate hypothesis that it will have a corrective effect on the intestinal flora by comparing urinary D-lactic acid levels.


Clinical Trial Description

Lactic acid exists as two optical isomers, L-lactic acid and D-lactic acid. These isomers are metabolized to or synthesized from pyruvate by the action of isomer-specific enzymes (L-lactate dehydrogenase and D-lactate dehydrogenase). Mammals, including humans, do not possess D-lactate dehydrogenase, and therefore D-lactate production in human tissue is very limited. The endogenous single D-lactate synthesis known in man is carried out by glyoxalase. In this pathway, methylglyoxal is converted into D-lactate by the enzymes glyoxalase-1 and glyoxalase-2. Due to this restricted production, the blood D-lactate level in healthy people is so low that L-lactate is the major physiological enantiomer of lactate in the human body. The bacterial flora in the human gastrointestinal tract has the ability to produce L and / or D-lactate depending on the amount of L-LDH and D-LDH present. Some strains of bacteria have the enzyme DL-lactate racemase to convert one isomer to another. Therefore, racemization reactions can further increase the amount of D-lactate isomers present in the column. Although there is no D-lactate dehydrogenase enzyme in humans, D-Lactate is metabolized into pyruvate by the enzyme D-2-hydroxy acid dehydrogenase (D-2-HDH), an intramitochondrial flavoprotein with high activity in the liver and renal cortex. The kidney's threshold for D-lactate is much lower than L-lactate and is efficiently excreted in urine as well as metabolic clearance. Thus, under normal conditions, D-lactate produced by tissue metabolism or bacterial fermentation in the gut; It does not cause a clinically significant increase in lactate in blood, urine or feces. D-lactic acidosis is a well-defined complication of short bowel syndrome due to the combination of altered gastrointestinal tract anatomy and abnormal bacterial flora. Many case reports reported in the literature are associated with short bowel syndrome secondary to various causes. There are studies investigating the effects of fermented formulas and probiotics on D-lactic acid in healthy babies. In these studies, no increased risk for D-lactic acidosis was found in healthy infants fed with probiotic supplemented formulas. Considering the studies on newborns; In babies with necrotizing enterocolit, it has been shown that urinary D-lactate excretion increased as a result of increased enteric bacterial activity. In another study, plasma D-lactic acid level was found to be high in premature babies with necrotizing enterocolitis. However, more detailed studies on newborns are needed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04620629
Study type Observational
Source Hacettepe University
Contact
Status Completed
Phase
Start date February 1, 2020
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05499481 - Short Against Long Antibiotic Therapy for Infected Orthopedic Sites Phase 3
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Completed NCT03199911 - Topical Antibiotic Prophylaxis for Eyelids Phase 4
Completed NCT05355571 - The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function and/or Faecal Microbiota Composition N/A
Recruiting NCT05699174 - PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation Phase 3
Completed NCT03087890 - Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria Phase 4
Completed NCT01254097 - Probiotics in Primary Care N/A
Recruiting NCT06018792 - Molecular Culture for the Diagnosis of Pediatric Sepsis
Completed NCT06030713 - Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome N/A
Active, not recruiting NCT05027893 - Complications After Lower Third Molar Surgery N/A
Not yet recruiting NCT03935828 - Effect of Topical Sinonasal Antibiotics Phase 2
Not yet recruiting NCT06383637 - Antibiotic Use and Resistance KAP Among Dental Interns
Enrolling by invitation NCT04707092 - Use of Preoperative and Postoperative Antimicrobial Treatment Phase 4
Not yet recruiting NCT06395454 - Usage of Procalcitonin to Reduce Antibiotics Duration in VAP in Neurosurgical ICU N/A
Recruiting NCT03932708 - Improving Antibiotic Use in Urgent Care Facilities N/A
Recruiting NCT04731025 - Local Antibiotics for Breast Implants Phase 3
Completed NCT04403334 - Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin Phase 4
Completed NCT04127682 - Antibiotic Prescription for Children With Acute Upper Respiratory Tract Infections in Assiut District
Completed NCT05742295 - Prevention of Cefoperazone-induced Coagulopathy Phase 4